AstraZeneca’s immunotherapy drug


U.S. FDA nods for AstraZeneca’s Imfinzi 

AstraZeneca’s immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer

Company: AstraZeneca 

Treatments Forlung cancer

General information about Imfinzi

Imfinzi, chemically known as durvalumab, belongs to a new class of immuno-oncology drugs that block a mechanism tumours use to evade detection from the immune system.

The approval was based on a trial involving 713 patients, showing patients survived on average 16.8 months without their disease worsening when given Imfinzi, against just 5.6 months for those on placebo.